MUMBAI (Reuters) - Sun Pharmaceutical Industries Ltd, India's largest drugmaker by revenue, reported a 15 percent jump in second-quarter net profit on Thursday, but slightly lagged estimates.
Net income for the quarter ended September was 15.72 billion rupees ($255.4 million), up from 13.62 billion rupees a year earlier. Analysts on average expected net income of 15.88 billion rupees, according to Thomson Reuters I/B/E/S.
Sun Pharma, which is in the process of acquiring rival drugmaker Ranbaxy Laboratories Ltd , is awaiting approval from India's antitrust regulator for the deal.
(1 US dollar = 61.5600 rupee)
(Reporting by Zeba Siddiqui in Mumbai; Editing by Prateek Chatterjee)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app